Kelly Hardes

871 citations

18 papers · 643 indexed · 1 hit paper · h-index 10

Co-authors: Andrew I. Bayliffe William Powley David A. Lipson Aili L. Lazaar Jason D. Christie Tracey J. Wright Germain Poirier Brian Zeno
Topics: Asthma and respiratory diseases (10 papers)Inhalation and Respiratory Drug Delivery (5 papers)Antibiotics Pharmacokinetics and Efficacy (3 papers)
Cited by: Infectious Diseases Neurology Pulmonary and Respiratory Medicine
Journals: Critical Care Medicine European Respiratory Journal Critical Care
Partner nations: United Kingdom United States Germany

In The Last Decade

Kelly Hardes

18 papers receiving 635 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

2017 452 citations Akram Khan, Brian Zeno et al. Critical Care profile →

Peers

Countries citing papers authored by Kelly Hardes

Since Specialization

Citations

This map shows the geographic impact of Kelly Hardes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly Hardes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly Hardes more than expected).

Fields of papers citing papers by Kelly Hardes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly Hardes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly Hardes. The network helps show where Kelly Hardes may publish in the future.

Co-authorship network of co-authors of Kelly Hardes

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly Hardes. A scholar is included among the top collaborators of Kelly Hardes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly Hardes. Kelly Hardes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma 2021 ·British Journal of Clinical Pharmacology ·Dave Singh,Rainard Fuhr,(unknown),(unknown),Kelly Hardes,(unknown),Anthony Cahn,Steven W. Yancey,Isabelle Pouliquen	34
2	A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study 2020 ·European Journal of Anaesthesiology ·(unknown),Andrew I. Bayliffe,Daniel F. McAuley,Joyce Yeung,David Thickett,(unknown),Ciara O’Donnell,(unknown),Tracey J. Wright,(unknown),Kelly Hardes,Charlotte Summers,(unknown),William Powley,Robert C. Wilson,Aili L. Lazaar,Andrew Fowler,Gavin D. Perkins	7
3	A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndromebreakdown → 2017 ·Critical Care ·Akram Khan,(unknown),Brian Zeno,Timothy E. Albertson,John H. Boyd,Jason D. Christie,Richard Hall,Germain Poirier,Juan J. Ronco,Mark Tidswell,Kelly Hardes,William Powley,Tracey J. Wright,Sarah Siederer,David Fairman,David A. Lipson,Andrew I. Bayliffe,Aili L. Lazaar	452
4	Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies 2016 ·Inflammation Research ·(unknown),Tim Schmidt,Disala Fernando,Kelly Hardes,Nicola Scott,Sara Brett,(unknown),(unknown),Bill Davis,Simon McHugh,(unknown)	15
5	Clinical Efficacy and Tolerability of a Novel Selective Corticosteroid in Atopic Dermatitis - Two Randomised Controlled Trials 2015 ·Skin Pharmacology and Physiology ·Sabine Dölle,(unknown),Philippe Bareille,Kelly Hardes,Jonathan Robertson,Margitta Worm	9
6	A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome 2015 ·Critical Care Medicine ·Jason D. Christie,Steven N. Vaslef,Philip K.‐Y. Chang,Addison K. May,Scott R. Gunn,Shuying Yang,Kelly Hardes,Lesley Kahl,William Powley,David A. Lipson,Andrew I. Bayliffe,Aili L. Lazaar	29
7	Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study 2014 ·Clinical Therapeutics ·Rashmi Mehta,Kelly Hardes,Dennis Kelleher,Andrew Preece,Lee Tombs,Noushin Brealey	10
8	Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study 2014 ·International Journal of COPD ·Rashmi Mehta,Kelly Hardes,Noushin Brealey,Lee Tombs,Andrew Preece,Dennis Kelleher	10
9	Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial 2013 ·Journal of Asthma ·Philippe Bareille,Kelly Hardes,Alison Donald	11
10	Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) 2013 ·Rashmi Mehta,Kelly Hardes,Dennis Kelleher,Andrew Preece,Lee Tombs,Noushin Brealey	3
11	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies 2013 ·Clinical Drug Investigation ·Anthony Cahn,Ruth Tal‐Singer,Isabelle Pouliquen,Rashmi Mehta,Andrew Preece,Kelly Hardes,Glenn Crater,(unknown)	21
12	Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) 2013 ·Dennis Kelleher,Kelly Hardes,Noushin Brealey,Lee Tombs,Andrew Preece,Rashmi Mehta	4
13	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies 2013 ·Current Drug Therapy ·Ann Allen,Philippe Bareille,Kelly Hardes,Jonathan Robertson	2
14	Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial 2013 ·Current Drug Therapy ·Philippe Bareille,Kelly Hardes,Jonathan Robertson,Angela Davis,Ann Allen	1
15	Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study 2013 ·Current Drug Therapy ·Philippe Bareille,Ann Allen,Kelly Hardes,Alison Donald	2
16	Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination 2012 ·Clinical Therapeutics ·Ann Allen,Angela Davis,Kelly Hardes,Lee Tombs,Rodger Kempsford	17
17	Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) 2011 ·European Respiratory Journal ·Dennis Kelleher,Andrew Preece,Rashmi Mehta,Alison Donald,Kelly Hardes,Anthony Cahn,Glenn Crater	4
18	Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults 2011 ·Rashmi Mehta,Kelly Hardes,Anthony Cahn,Amy Newlands,Alison Donald,Andrew Preece,Dennis Kelleher,Glenn Crater	12

About Kelly Hardes

Kelly Hardes is a scholar working on Immunology and Allergy, Physiology and Pulmonary and Respiratory Medicine, having authored 18 papers that have together received 643 indexed citations. Recurring topics across this work include Asthma and respiratory diseases (10 papers), Inhalation and Respiratory Drug Delivery (5 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). The work is most often cited by research in Infectious Diseases (358 citations), Neurology (116 citations) and Pulmonary and Respiratory Medicine (160 citations). Kelly Hardes has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Andrew I. Bayliffe, William Powley, David A. Lipson, Aili L. Lazaar, Jason D. Christie, Tracey J. Wright, Germain Poirier, Brian Zeno, Akram Khan and David Fairman. Their work appears in journals such as Critical Care Medicine, European Respiratory Journal and Critical Care.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact